{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:46:11Z","timestamp":1792057571908,"version":"4.4.0"},"reference-count":28,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Concentration\u2010QTc analysis from Phase 1 studies is increasingly used to evaluate QTc prolongation risk as an alternative to thorough QT (TQT) studies. According to International Conference on Harmonization E14 documents, such analyses should include exposures at twice the highest clinically relevant exposure instead of a positive control to establish electrocardiogram (ECG) assay sensitivity; however, achieving this may be challenging when the highest dose in Phase 1 studies is restricted for various reasons. This study evaluated the QTc prolongation risk of forvisirvat via concentration\u2010QTc analysis and demonstrated ECG assay sensitivity via the well\u2010described meal effect. A double\u2010blind, randomized, placebo\u2010controlled, single ascending dose study evaluated the effect of forvisirvat on ECG parameters following single oral doses up to 80 mg in 32 healthy adults. Time\u2010matched plasma forvisirvat concentrations and 12\u2010lead ECG data were collected. The prespecified linear mixed\u2010effects model assessed the impact of forvisirvat on baseline\u2010 and placebo\u2010adjusted QT interval corrected by the Fridericia method (\u0394\u0394QTcF). ECG assay sensitivity was established by prospectively evaluating the postprandial QTcF shortening. The two\u2010sided 90% confidence interval (CI) for the model\u2010predicted \u0394\u0394QTcF was below 10 ms up to the maximum observed plasma concentration of 703 ng\/mL. Meal\u2010induced QTcF shortening was \u22126.38 ms (95% CI, \u22128.51 to \u22124.26) at 4 h after the standardized lunch, with the two\u2010sided 95% CI below 0. Forvisirvat showed no QTcF prolongation, and ECG assay sensitivity was confirmed via meal\u2010induced QTcF shortening. These results supported regulatory acceptance of a TQT study waiver by the Japanese Pharmaceuticals and Medical Devices Agency.<\/jats:p>","DOI":"10.1002\/jcph.70312","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:59:26Z","timestamp":1792054766000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concentration\u2010QTc Analysis Supporting Thorough QT Study Waiver for Forvisirvat: Electrocardiogram Assay Sensitivity Demonstrated via Meal Effect"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0152-0238","authenticated-orcid":false,"given":"Yushi","family":"Kashihara","sequence":"first","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Igawa","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7541-3074","authenticated-orcid":false,"given":"Kei","family":"Okita","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Ohara","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakatsu","family":"Kotsuma","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Yoshihara","sequence":"additional","affiliation":[{"name":"Daiichi Sankyo Co., Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"ICH E14 guideline: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. Accessed May 28 2026.https:\/\/www.pmda.go.jp\/files\/000156582.pdf"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.224"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007307881"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/CPT.60"},{"key":"e_1_2_11_6_1","unstructured":"ICH E14\/S7B Q&As: clinical and nonclinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential. Accessed May 28 2026.https:\/\/www.pmda.go.jp\/files\/000247627.pdf."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010025\u201009985\u20104"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010017\u20109558\u20105"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010025\u201009981\u20108"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1488"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2574465"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1003"},{"key":"e_1_2_11_13_1","unstructured":"Food and Drug Administration. EVRYSDI. Accessed December 22 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2020\/213535Orig1s000SumR.pdf"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3284"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011419851"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12371"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2012.04376.x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1374"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14933"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.935"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.370"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136369"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.804"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2596"},{"key":"e_1_2_11_25_1","unstructured":"DarpoB.The early precision QT approach. Published 2025. Accessed June 9 2026.https:\/\/clario.com\/wp\u2010content\/uploads\/2025\/01\/WhitePaper_CS_TheEPQTApproach_15Jan2025.pdf"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.2307\/2533558"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jelectrocard.2014.11.006"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.975"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/75.4.800"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70312","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70312","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70312","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T08:59:28Z","timestamp":1792054768000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/jcph.70312"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70312","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70312"}}